Follow last change Nov 2025 re-read 9 days ago

CD19

targets CD19

Developed for: B-cell acute lymphoblastic leukemia
Investigated by: Affiliated Hospital of Nantong University · Jiangsu Province Natural Science Foundation of China (Grant No. BK20210091) · Jining Medical University · National Natural Science Foundation of China · Northern Jiangsu People's Hospital · Suzhou Hospital of Traditional Chinese Medicine
+3 more
· The First Affiliated Hospital of Bengbu Medical University · The First Affiliated Hospital of Soochow University · The Second People's Hospital of Huai'an

today NCT05470777 · Ph 2

20202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT05470777	Jan 2020 → Jul 2027 expected	B-cell acute lymphoblastic leukemia	The First Affiliated Hospital of Soochow University	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	CD19	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05470777 ↗
Route	Other	“received sequential infusion of CD22 and CD19 CAR-T cells” NCT05470777 ↗
Target	CD19	“sequential CD22/CD19 CAR T cells” PMID 41199560 ↗ Nov 2025